STRUCTURE, EFFICACY AND ECONOMY OF THE THERAPY OF HYPERTENSION IN SLOVAK OUT-WARD PATIENTS WITH METABOLIC SYNDROME – PROJECT NEMESYSRNRN

Introduction. Increased blood pressure is one of discriminant criteria for presence of metabolic syndrome (MS). Despite of  numerous analyses of antihypertensive therapy,  its evaluation in association to MS are seldom.
Method: Crosssectional multicentric screening of MS and structure of medication was performed in  8679 consequetive out-ward patients in whole territory of Slovakia. MS
was defined according to IDF criteria (IDF 2005).
Results. Out-ward patients aged 52.4±16.1 yrs [17-96 yrs] exhibited 25.6% prevalence of  MS (23.7% in males; 26.9% in females; p<0.01). Hypertension (BP≥140/90 mmHg) or antihypertensive therapy  were present in 65.8% pts. Target blood pressure for MS [BP <130/85 mm Hg] was reached in 13.3% of MS+ pts and 14.7% of MS- of treated hypertensive patients (NS). MS + pts were more often unsuccessfully treated (70.1% vs. 54.4%; p<0.001). Both subgroups had similar structure of therapy, however, MS+ pts were treated more expensively – antihypertensive therapy was 14.9 vs 13.1 SK of  DDD (p<0.001); hypolipodemic therapy was 12.3 vs 10.7 SK of DDD (p<0.001); and whole therapy was 34.7 vs 30.3 SK of DDD (p<0.01).
Conclusion: Project NEMESYS found 25.6% prevalence of  metabolic syndrom between out-ward patients. Their antihypertensive and hypolipidemic therapies were more expensive and equally efficient (resp. non.efficient) in comparison with patients without MS. Only 14% of pts reached normotension.